CRMDCorMedix Inc.
Pharmaceutical Preparations
- Revenue
- $312M
- 617% YoY
- Operating margin
- 48.2%
- 194% YoY
- EBITDA
- $151M
- 779% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear107% of net incomeCash flow under 80% of net income
- Dilutive SBCClear4% of revenueOver 10% of revenue
- Payouts exceed cash flowClear0% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear3% of assetsOver 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $191K | $65K | — | $43M | $312M | 617% |
| Operating income | −$29M | −$31M | −$49M | −$22M | $150M | 772% |
| Net income | −$28M | −$30M | −$46M | −$18M | $163M | 1009% |
| Operating cash flow | −$21M | −$24M | −$38M | −$51M | $175M | 446% |
| Capex | $1M | $219K | $327K | $116K | $2M | 1848% |
| Stock-based comp | $5M | $4M | $5M | $6M | $14M | 126% |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | — | — | 276 | — |
| FY2024 | — | — | 192 | — |
| FY2023 | — | — | 89 | — |